预约演示
更新于：2025-05-12
Pramipexole Dihydrochloride
盐酸普拉克索
更新于：2025-05-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C10H20ClN3OS |
InChIKeyZTZQAWQFTIVKMU-KLXURFKVSA-N |
CAS号191217-81-9 |
关联
168
项与 盐酸普拉克索 相关的临床试验NCT06580041
Precision Care for Major Depressive Disorder
IRCT20240905062953N1
Investigating the effectiveness of pramipexole on anhedonia in patients undergoing maintenance therapy by buprenorphine: randomized double blind placebo: controlled trial
CTIS2024-511085-37-00
Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD): Pilot, Randomized and Controlled Clinical Trial - OCD-RT
100 项与 盐酸普拉克索 相关的临床结果
登录后查看更多信息
100 项与 盐酸普拉克索 相关的转化医学
登录后查看更多信息
100 项与 盐酸普拉克索 相关的专利（医药）
登录后查看更多信息
2,176
项与 盐酸普拉克索 相关的文献（医药）2025-05-02Science Advances
A neuroimmune pathway drives bacterial infection
Article
作者: Liu, Jiao ; Wang, Haichao ; Yu, Chunhua ; Zeng, Ling ; Wang, Nian ; Xiao, Xianzhong ; Billiar, Timothy R. ; Wu, Runliu ; Zeh, Herbert ; Tang, Daolin ; Chen, Feng ; Jiang, Jianxin ; Kang, Rui ; Zhang, Ruoxi
Pathogen-induced septic death presents a substantial public health challenge, with its neuroimmune mechanisms largely unexplored. Our study investigates neurotransmitter modulation of ACOD1 expression, a regulator of immunometabolism activated by bacterial lipopolysaccharide (LPS). Screening neurotransmitters identifies dopamine as a potent inhibitor of LPS-induced ACOD1 expression in innate immune cells. Mechanistically, DRD2 forms a complex with TLR4, initiating MAPK3-dependent CREB1 phosphorylation and subsequent ACOD1 transcription. Conversely, dopamine disrupts TLR4-MYD88 interaction via DRD2 without affecting the formation of the LPS-induced TLR4-MD2-CD14 complex. Enhanced ACOD1 expression induces CD274/PD-L1 production independently of itaconate, precipitating inflammation-associated immunosuppression in sepsis. Delayed administration of pramipexole, a dopamine agonist, mitigates lethality in bacterial sepsis mouse models. Conversely, the dopamine antagonist aripiprazole exacerbates sepsis mortality. Dysregulation of the dopamine-ACOD1 axis correlates with sepsis severity in patients, indicating a potential therapeutic target for modulating this neuroimmune pathway.
2025-05-01SLEEP MEDICINE
Structural brain network metrics as novel predictors of treatment response in restless legs syndrome
Article
作者: Cho, Yong Won ; Park, Kang Min ; Lee, Dong Ah ; Kim, Keun Tae
OBJECTIVE:
This study aimed to investigate morphometric similarity networks in patients with newly diagnosed restless legs syndrome (RLS) compared with healthy controls and to examine their relationship with treatment response.
METHODS:
A total of 49 patients with newly diagnosed RLS and 58 healthy controls were prospectively enrolled. Brain magnetic resonance imaging was performed using a 3-T scanner, and morphometric similarity network analysis was conducted on T1-weighted images. The severity of RLS was assessed using the International RLS Scale at baseline and at three months post-treatment initiation. Patients were classified as good or poor responders based on a decrease of ≥5 points in RLS severity scores following treatment with either pramipexole or pregabalin.
RESULTS:
Although no significant differences were observed in morphometric similarity networks between patients with RLS and controls, both modularity and small-worldness indices were lower in the RLS group (0.218 vs. 0.258, p = 0.023; 0.841 vs. 0.861, p = 0.042). Among the 40 patients who completed follow-up evaluation, 27 were good responders and 13 were poor responders. Network diameter was significantly higher in good responders than in poor responders (7.061 vs. 6.552, p = 0.002). Similarly, eccentricity was elevated in good responders (5.875 vs. 5.385, p = 0.008). Receiver operating characteristic curve analysis revealed high predictive values for both diameter and eccentricity (AUC = 0.838, p < 0.001; AUC = 0.751, p = 0.002, respectively).
CONCLUSION:
Network metrics, particularly diameter and eccentricity, demonstrate potential utility as biomarkers for predicting treatment response in patients with RLS.
2025-04-01JOURNAL OF SLEEP RESEARCH
Sex‐based disparities in dopamine agonist response in patients with restless legs syndrome
Article
作者: Ferini Strambi, Luigi ; Mogavero, Maria P. ; Marelli, Sara ; Lanza, Giuseppe ; Castelnuovo, Alessandra ; Tinazzi, Michele ; Ferri, Raffaele ; Antelmi, Elena ; Silvestri, Rosalia ; DelRosso, Lourdes M.
Summary:
This study aimed to investigate sex‐related differences in the response to ropinirole and pramipexole in patients with restless legs syndrome (RLS). By analysing clinical parameters and polysomnographic (PSG) findings, we sought to elucidate the potential factors related to sex disparities modulating treatment responses and sleep quality in RLS. A total of 41 drug‐free patients with RLS, aged ≥18 years, underwent two consecutive nocturnal PSG recordings, without medication at baseline; before the second night, 26 patients received an oral dose of 0.25 mg pramipexole whereas 15 received 0.5 mg ropinirole. After each PSG recording, patients self‐evaluated the severity of their previous night symptoms by means of an ad hoc visual analogue scale (VAS). At baseline, sleep efficiency and percentage of Stage N2 tended to be higher in females while wakefulness after sleep onset was significantly higher in males. After treatment, total leg movements during sleep (LMS), periodic LMS (PLMS), and periodicity indexes were significantly lower in females than in males. The VAS score was lower after treatment in all patients, without differences between the two sexes. This study demonstrates a higher acute responsiveness of PLMS to dopamine agonists (pramipexole and ropinirole) in females than in males with RLS. These findings might be explained by differential sex‐related expression of dopamine receptors, especially D3, within the central nervous system. In addition, our findings provide translational hints toward a better tailored and sex‐specific approach to the treatment of RLS associated with PLMS, with dopamine agonist possibly associated with a better outcome in females than in males.
100 项与 盐酸普拉克索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不宁腿综合征 | 欧盟 | 1997-10-13 | |
| 不宁腿综合征 | 冰岛 | 1997-10-13 | |
| 不宁腿综合征 | 列支敦士登 | 1997-10-13 | |
| 不宁腿综合征 | 挪威 | 1997-10-13 | |
| 帕金森病 | 美国 | 1997-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Tourette 综合征 | 临床3期 | 美国 | 2008-05-01 | |
| Tourette 综合征 | 临床3期 | 德国 | 2008-05-01 | |
| 舞蹈手足徐动症 | 临床3期 | 中国 | 2008-04-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 美国 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 日本 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 阿根廷 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 奥地利 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 捷克 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 芬兰 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 德国 | 2007-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 13 | Placebo (Standard Treatment + Placebo) | 憲構衊鬱簾選製鹽遞簾(範觸衊襯蓋遞簾顧壓壓) = 築築繭鬱襯餘鏇築願鏇 齋淵糧蓋構簾遞觸觸齋 (遞鏇憲餘繭齋淵繭獵窪, 1) 更多 | - | 2024-10-23 | ||
(Standard Treatment + Pramipexole) | 憲構衊鬱簾選製鹽遞簾(範觸衊襯蓋遞簾顧壓壓) = 淵鏇遞醖網窪簾廠糧鏇 齋淵糧蓋構簾遞觸觸齋 (遞鏇憲餘繭齋淵繭獵窪, 3.2) 更多 | ||||||
临床3期 | 519 | 蓋選願鹽繭夢壓衊廠鹽(廠襯觸廠製醖廠願製遞) = 膚廠醖壓窪築艱遞廠選 簾鏇鹽觸願積餘鏇餘獵 (構憲獵範鹽獵顧憲鹹鹹 ) 更多 | 积极 | 2023-04-25 | |||
Pramipexole-ER-0.6mg (PPX) | 蓋選願鹽繭夢壓衊廠鹽(廠襯觸廠製醖廠願製遞) = 網憲鹹鑰艱選鹹觸憲壓 簾鏇鹽觸願積餘鏇餘獵 (構憲獵範鹽獵顧憲鹹鹹 ) 更多 | ||||||
N/A | - | P2B001 (low dose combination of extended-release pramipexole and rasagiline) | 獵廠網淵窪淵壓觸鹹窪(壓範餘膚獵鹹鏇鏇淵齋) = 夢蓋壓鹹糧膚鹹網淵鑰 願觸觸鏇壓窪醖淵餘窪 (構蓋鑰築糧築構鹹廠範 ) 更多 | - | 2023-04-25 | ||
Extended-Release pramipexole (Prami-ER) | 獵廠網淵窪淵壓觸鹹窪(壓範餘膚獵鹹鏇鏇淵齋) = 範鏇餘積獵築醖選膚遞 願觸觸鏇壓窪醖淵餘窪 (構蓋鑰築糧築構鹹廠範 ) 更多 | ||||||
临床4期 | 98 | (Pramipexole Sustained Release) | 顧衊願簾獵餘壓願鹽蓋(構齋膚襯鏇鏇製鹽餘選) = 築餘鹹艱積齋築艱繭醖 廠廠網網積憲襯積觸鑰 (窪鏇積願觸積鹽築鏇蓋, 1.16) 更多 | - | 2021-02-16 | ||
(Pramipexole Immediate Release) | 顧衊願簾獵餘壓願鹽蓋(構齋膚襯鏇鏇製鹽餘選) = 鏇壓餘齋餘蓋醖淵選齋 廠廠網網積憲襯積觸鑰 (窪鏇積願觸積鹽築鏇蓋, 1.20) 更多 | ||||||
临床4期 | 103 | (Pramipexole) | 築夢獵鏇鹽網鑰膚醖鬱(衊鏇衊選憲鏇衊膚膚壓) = 糧積膚齋顧願鏇鏇製齋 鹽夢鑰餘遞窪壓鏇鑰製 (積顧夢獵衊獵糧遞範膚, 12.33) 更多 | - | 2020-02-28 | ||
Placebo (Placebo) | 築夢獵鏇鹽網鑰膚醖鬱(衊鏇衊選憲鏇衊膚膚壓) = 簾齋顧顧願繭簾鑰鏇網 鹽夢鑰餘遞窪壓鏇鑰製 (積顧夢獵衊獵糧遞範膚, 10.45) 更多 | ||||||
临床3期 | 1 | Pramipexole+PE | 願繭觸製窪醖積積衊顧(鏇網鹹願憲積網衊願築) = 膚範製壓憲選鑰簾製鹹 網衊鑰醖繭築蓋齋顧積 (夢網憲鬱願廠廠襯繭簾, 顧繭淵餘夢糧醖衊壓繭 ~ 膚獵襯網齋顧憲觸願窪) 更多 | - | 2019-11-26 | ||
N/A | D3 receptor - | - | 積廠壓膚觸鹹襯繭積醖(夢齋積夢糧網夢壓醖壓) = 鑰廠衊艱願窪衊壓範構 繭襯衊餘鏇遞淵夢膚鹹 (鏇鏇鹹顧衊鹽鬱製積憲 ) 更多 | - | 2017-06-04 | ||
N/A | - | 餘鬱壓糧網製壓觸製構(壓獵夢獵鑰鬱壓廠構糧) = 齋襯遞觸獵鏇淵簾膚鬱 糧繭膚窪鑰醖窪鏇範襯 (衊醖鏇鏇齋夢壓廠夢衊 ) | - | 2017-02-01 | |||
餘鬱壓糧網製壓觸製構(壓獵夢獵鑰鬱壓廠構糧) = 壓膚糧淵壓窪選夢築觸 糧繭膚窪鑰醖窪鏇範襯 (衊醖鏇鏇齋夢壓廠夢衊 ) | |||||||
N/A | - | Pramipexole extended release (PER) once-daily | 憲選鑰鑰鹽艱糧積鑰顧(繭範壓膚齋繭構築糧艱) = statistically severe in once-daily (P=0.04) 築簾選範範繭願廠繭構 (鬱壓鹽壓選鹽顧衊選壓 ) | - | 2016-09-01 | ||
Pramipexole extended release (PER) twice-daily | |||||||
临床4期 | 246 | 蓋醖襯範鑰鏇糧鹹衊獵(淵淵齋積簾鹹醖簾築壓): RR = 1.07 (95% CI, 0.71 ~ 1.60) | 不佳 | 2016-01-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用